Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç, +157

The Lancet Oncology

Hematological MalignancyMedicineHematologyMyeloid NeoplasiaPharmacotherapy +4

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Srđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi, +191

The Lancet

Hematological MalignancyBone Marrow FailureMomelotinib Versus DanazolSymptomatic PatientsHematology +4

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

Vânia Hungria, Paweł Robak, Marek Hus, +36

New England Journal of Medicine

Thalidomide treatment of resistant or relapsed multiple myeloma patients.

Marek Hus, Anna Dmoszyńska, Maria Soroka‐Wojtaszko, +7

PubMed

Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma

Marek Hus, Norbert Grząśko, Marta Szostek, +10

Annals of Hematology

Assessment of red blood cell distribution width as a prognostic marker in chronic lymphocytic leukemia

Monika Podhorecka, Dorota Halicka, Agnieszka Szymczyk, +4

Oncotarget

Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis

Ruben A. Mesa, Claire Harrison, Stephen T. Oh, +15

Leukemia

Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients

Norbert Grząśko, Marek Hus, Andrzej Pluta, +6

Hematological Oncology

Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials

Srđan Verstovšek, Ruben A. Mesa, Vikas Gupta, +16

Blood Advances

Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG)

Elżbieta Iskierka‐Jazdzewska, Marek Hus, Krzysztof Giannopoulos, +19

Leukemia & lymphoma/Leukemia and lymphoma

Clinical EndpointPharmacotherapyAdverse Drug ReactionHematological MalignancyOncology +19